JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $76,000 | -13.6% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q3 2020 | $88,000 | +17.3% | 10,816 | 0.0% | 0.01% | +12.5% |
| Q2 2020 | $75,000 | +47.1% | 10,816 | 0.0% | 0.01% | +14.3% |
| Q1 2020 | $51,000 | -45.7% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q4 2019 | $94,000 | +161.1% | 10,816 | 0.0% | 0.01% | +125.0% |
| Q3 2019 | $36,000 | -33.3% | 10,816 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $54,000 | -19.4% | 10,816 | 0.0% | 0.01% | -14.3% |
| Q1 2019 | $67,000 | +86.1% | 10,816 | 0.0% | 0.01% | +75.0% |
| Q4 2018 | $36,000 | -48.6% | 10,816 | 0.0% | 0.00% | -42.9% |
| Q3 2018 | $70,000 | -15.7% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q2 2018 | $83,000 | -66.3% | 10,816 | -1.8% | 0.01% | -69.0% |
| Q1 2018 | $246,000 | -55.1% | 11,016 | -74.4% | 0.03% | -52.5% |
| Q4 2017 | $548,000 | -18.2% | 43,016 | 0.0% | 0.06% | -22.8% |
| Q3 2017 | $670,000 | – | 43,016 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
| Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
| TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
| Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
| Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
| PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
| Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
| RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |